GO:0045453 bone resorption: Osteoclast-Mediated Bone Degradation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045453 (bone resorption) is the biological process in which specialized osteoclasts degrade both the organic and inorganic portions of bone and endocytose and transport the degradation products.
• Osteoclast-mediated bone resorption is a tightly regulated process that supports skeletal remodeling, calcium homeostasis, and immunometabolism.
• Matrix metalloproteinases (MMPs) and acid-secreting machinery are central to the degradation of the organic and inorganic bone matrix during resorption.
• Dysregulated bone resorption underlies clinical disorders including osteoporosis, hemophilia-related bone loss, chronic otitis media with bone destruction, and cancer-associated bone disease.
• MicroRNAs and lipids are emerging key regulators of osteoclast-mediated bone resorption, offering new therapeutic and research targets.
• Time-lapse in vivo imaging enables direct visualization and quantification of bone resorption and formation dynamics.
Description
Bone resorption (GO:0045453) is the biological process in which specialized cells known as osteoclasts degrade the organic and inorganic portions of bone, and endocytose and transport the degradation products. This process is fundamental to skeletal homeostasis, allowing the continuous renewal of bone tissue through coupled resorption and formation. Beyond its structural role, bone resorption supports systemic calcium and phosphate balance and contributes to immunometabolic regulation. Researchers study bone resorption to understand skeletal physiology, to dissect the molecular control of osteoclast activity, and to develop interventions for disorders characterized by excessive or insufficient bone degradation. The process is regulated at multiple levels, including microRNA-mediated control of osteoclast gene expression and lipid-dependent signaling pathways. Matrix metalloproteinases (MMPs) are key effectors that cleave organic matrix components during resorption, linking osteoclast activity to remodeling and repair. Clinically, altered bone resorption is observed in hemophilia, chronic otitis media, and a spectrum of metabolic bone diseases, making it a central topic in translational musculoskeletal research.
bone resorption At A Glance
| GO ID | GO:0045453 |
|---|---|
| GO term | bone resorption |
| Ontology | biological_process |
| Synonym | none |
| Definition | The process in which specialized cells known as osteoclasts degrade the organic and inorganic portions of bone, and endocytose and transport the degradation products. |
| Major function | Osteoclast-mediated degradation of bone matrix supporting skeletal remodeling, calcium homeostasis, and immunometabolism |
| Key cell type | Osteoclast |
| Key effectors | Matrix metalloproteinases (MMPs), acid-secreting machinery, and osteoclast-specific signaling proteins |
| Related processes | Bone remodeling, bone formation, osteoclast differentiation, and mineral homeostasis |
What Is GO:0045453?
According to the Gene Ontology, bone resorption (GO:0045453) is the process in which specialized cells known as osteoclasts degrade the organic and inorganic portions of bone, and endocytose and transport the degradation products. In practical terms, osteoclasts dissolve the mineral phase and digest the proteinaceous matrix of bone, then internalize and traffic the resulting degradation products. This definition distinguishes bone resorption from bone formation and from general bone remodeling, focusing specifically on the osteoclast-driven degradative arm of skeletal turnover.
Why Is bone resorption Important in Cell Biology?
Bone resorption is essential for skeletal maintenance and systemic mineral homeostasis, and its dysregulation is directly implicated in common and rare human diseases. Because osteoclasts degrade both the organic and inorganic bone matrix, perturbations in this process can lead to bone loss, fragility, or defective remodeling. Understanding the molecular regulation of bone resorption, including microRNA and lipid control of osteoclast activity, is therefore critical for identifying therapeutic targets and biomarkers. Clinical disorders of bone resorption range from metabolic bone diseases to hemophilia-associated bone loss and chronic otitis media with bone destruction, underscoring the broad medical relevance of this GO term.
• Maintains skeletal integrity through coupled bone resorption and formation during remodeling.
• Regulates systemic calcium and phosphate homeostasis via osteoclast-mediated matrix degradation.
• Supports immunometabolism by releasing factors that influence immune cell function.
• Is dysregulated in hemophilia, contributing to increased bone resorption and skeletal complications.
• Is controlled by microRNAs that modulate osteoclast differentiation and resorptive activity.
• Is influenced by lipids, revealing metabolic regulation of osteoclast function.
• Involves matrix metalloproteinases that degrade organic bone matrix during resorption and repair.
• Underlies clinical disorders of bone resorption such as osteoporosis and Paget disease.
• Contributes to bone destruction in chronic otitis media through osteoclast activity.
• Can be visualized and quantified in vivo using time-lapse imaging approaches.
What Happens During bone resorption?
Osteoclast Activation and Polarization
In simple terms: Osteoclasts are the bone-degrading cells, and they must first be activated and organized before they can dissolve bone.
Bone resorption begins with the activation and polarization of osteoclasts, the specialized cells responsible for degrading bone matrix. Osteoclasts form a sealed compartment against the bone surface, enabling localized degradation of both organic and inorganic components. This step is regulated by microRNAs and lipid signaling pathways that control osteoclast differentiation and functional maturation.
Acidification and Inorganic Matrix Dissolution
In simple terms: The osteoclast pumps acid into a sealed pocket to dissolve the mineral part of bone.
Osteoclasts secrete acid into the resorption lacuna, dissolving the inorganic mineral phase of bone. This acidification is a prerequisite for subsequent enzymatic degradation of the organic matrix. Disruption of this step impairs bone resorption and is linked to clinical disorders of bone resorption.
Proteolytic Degradation of Organic Matrix by MMPs
In simple terms: Enzymes called MMPs cut up the protein scaffold of bone after the mineral is removed.
Matrix metalloproteinases (MMPs) degrade the organic portion of bone matrix during resorption, remodeling, and repair. MMP activity is essential for processing collagen and other matrix proteins exposed after mineral dissolution. Dysregulated MMP activity contributes to pathological bone resorption in disease settings.
Endocytosis and Transport of Degradation Products
In simple terms: After breaking down bone, the osteoclast swallows the debris and moves it through the cell.
Following degradation, osteoclasts endocytose and transport the degradation products, as specified in the GO:0045453 definition. This transcellular transport is part of the resorptive cycle and contributes to the release of matrix-derived factors. The process supports immunometabolic signaling through the handling of bone-derived components.
Coupling to Bone Formation and Remodeling
In simple terms: Bone resorption is balanced by bone formation so that skeletal integrity is maintained.
Bone resorption is functionally coupled to bone formation during remodeling, and time-lapse imaging has been used to visualize and quantify these coupled events in vivo. Imbalances in this coupling lead to net bone loss or defective repair. Clinical disorders of bone resorption reflect disruptions in this balance.
Key Genes Involved in GO:0045453 bone resorption
The following genes and proteins are central to osteoclast-mediated bone resorption and are frequently studied in this process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MMP9 | Matrix metalloproteinase that degrades organic bone matrix | Key effector of bone resorption and remodeling |
| MMP13 | Collagenase involved in bone matrix degradation | Studied in bone resorption and repair |
| MMP2 | Gelatinase contributing to matrix turnover | Implicated in bone resorption and remodeling |
| MMP14 | Membrane-type MMP involved in matrix processing | Relevant to osteoclast-mediated degradation |
| CTSK | Cathepsin K, a protease for collagen degradation | Central to osteoclast resorptive activity |
| ACP5 | Tartrate-resistant acid phosphatase, osteoclast marker | Used to assess osteoclast function |
| NFATC1 | Transcription factor for osteoclast differentiation | Master regulator of osteoclastogenesis |
| FOS | AP-1 component required for osteoclast differentiation | Studied in osteoclast-mediated resorption |
| MITF | Transcription factor cooperating in osteoclast gene expression | Regulates osteoclast function |
| TNFRSF11A | RANK receptor driving osteoclast differentiation | Key signaling node in bone resorption |
| TNFSF11 | RANKL ligand that stimulates osteoclastogenesis | Central cytokine controlling bone resorption |
| TNFRSF11B | Osteoprotegerin, decoy receptor for RANKL | Regulates bone resorption balance |
| SRC | Kinase required for osteoclast sealing zone function | Studied in osteoclast activity |
| CLCN7 | Chloride channel supporting acidification | Required for inorganic matrix dissolution |
| TCIRG1 | V-ATPase subunit for osteoclast acid secretion | Essential for bone resorption |
| ATP6V0D2 | V-ATPase subunit in osteoclasts | Supports resorption lacuna acidification |
| CA2 | Carbonic anhydrase generating protons for acidification | Required for bone resorption |
How Is bone resorption Regulated?
Bone resorption is regulated at multiple levels, including microRNA-mediated control of osteoclast gene expression and lipid-dependent signaling pathways. MicroRNAs modulate osteoclast differentiation and resorptive activity, making them attractive targets for therapeutic intervention. Lipids influence osteoclast-mediated bone resorption, linking metabolic status to skeletal degradation. Matrix metalloproteinases provide additional regulatory control by processing matrix components during resorption and repair. Clinically, dysregulation of these pathways contributes to disorders of bone resorption such as osteoporosis and hemophilia-associated bone loss.
bone resorption and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFSF11 | Osteoporosis and increased bone resorption | Knockout or overexpression in osteoclast precursor cells |
| TNFRSF11B | Disorders of bone resorption balance | Knock-in of patient variants |
| CTSK | Pycnodysostosis and osteoclast dysfunction | Point-mutation knock-in models |
| MMP9 | Bone resorption in inflammatory disease | Knockout and overexpression models |
| TCIRG1 | Malignant infantile osteopetrosis | Knockout and point-mutation models |
Osteoporosis and Metabolic Bone Disorders
Increased bone resorption is a hallmark of osteoporosis and other clinical disorders of bone resorption, leading to reduced bone mass and increased fracture risk. The balance between osteoclast-mediated degradation and bone formation is disrupted in these conditions. Understanding the molecular regulation of bone resorption is essential for developing targeted therapies.
Hemophilia-Associated Bone Loss
Hemophilia is associated with increased bone resorption, contributing to skeletal complications in affected patients. The mechanisms linking coagulation disorders to osteoclast activity are an active area of research. This highlights the broader systemic influences on bone resorption beyond classical bone metabolism.
Chronic Otitis Media and Bone Destruction
Bone resorption plays a role in chronic otitis media, where osteoclast activity contributes to bone destruction in the middle ear. The osteoclast is a key mediator of this pathological bone loss. This illustrates how bone resorption can be triggered in inflammatory contexts outside the skeleton.
Cancer-Associated Bone Disease
Bone resorption is frequently dysregulated in cancer-associated bone disease, where tumor cells stimulate osteoclast activity. The immunometabolic role of bone resorption further links it to tumor microenvironment interactions. Targeting osteoclast-mediated resorption is a therapeutic strategy in this setting.
From bone resorption-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for osteoclast-mediated bone resorption? | Knockout cell model |
| Does a specific patient variant alter osteoclast function? | Point-mutation knock-in model |
| How does a fusion tag affect osteoclast protein localization? | Tagged knock-in model |
| Does overexpression of a gene increase bone resorption? | Overexpression cell model |
| Which genes regulate osteoclast differentiation at scale? | CRISPR library screening |
| What pathways are altered in resorption-defective cells? | Bioinformatics analysis of transcriptomic data |
How to Study the bone resorption Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Time-lapse imaging | Bone resorption and formation dynamics in vivo | Quantifying resorptive activity over time |
| Osteoclast resorption assays | Matrix degradation by osteoclasts | Evaluating gene effects on resorption |
| MMP activity assays | Proteolytic degradation of organic matrix | Studying matrix metalloproteinase function |
| Transcriptomic profiling | Gene expression changes in osteoclasts | Identifying regulators of bone resorption |
| MicroRNA target analysis | MicroRNA-mediated regulation | Dissecting post-transcriptional control |
| Lipid profiling | Lipid-dependent signaling in osteoclasts | Linking metabolism to resorption |
| Clinical biomarker analysis | Markers of bone resorption in patients | Monitoring disease activity |
| Bioinformatics pathway enrichment | Pathways associated with resorption genes | Discovering novel mechanisms |
In Vivo Time-Lapse Imaging
Time-lapse imaging enables in vivo visualization and quantification of bone resorption and bone formation dynamics. This approach provides direct measurements of resorptive activity over time. It is particularly useful for studying coupling between resorption and formation.
Osteoclast Functional Assays
Osteoclast-mediated bone resorption can be assessed using functional assays that measure matrix degradation and osteoclast activity. These assays are used to evaluate the effects of microRNAs and lipids on resorption. Matrix metalloproteinase activity is often measured as a readout of organic matrix degradation.
Transcriptomic and Bioinformatics Analysis
Transcriptomic profiling combined with bioinformatics can identify genes and pathways regulating bone resorption. MicroRNA target prediction and pathway enrichment help dissect regulatory networks. These methods support the discovery of novel regulators of osteoclast function.
Clinical and Translational Studies
Clinical studies of bone resorption disorders provide insights into disease mechanisms and potential therapeutic targets. Hemophilia and chronic otitis media are examples where bone resorption is clinically relevant. Translational research links molecular findings to patient outcomes.
How CRISPR Can Be Used to Study GO:0045453 bone resorption
Knockout
CRISPR knockout models are used to delete candidate genes and determine whether they are required for osteoclast-mediated bone resorption. Knockout of MMP genes, for example, can reveal their contribution to organic matrix degradation. These models are foundational for causal gene discovery in bone resorption research.
Point Mutation
Point-mutation knock-in models allow researchers to introduce specific patient variants into genes involved in bone resorption. This approach helps determine whether a variant alters osteoclast function or resorptive capacity. It is particularly useful for studying clinical disorders of bone resorption.
Knock-in
Knock-in models can be used to tag endogenous proteins or introduce reporter constructs to study osteoclast biology. Tagged knock-in of resorption-related genes enables visualization of protein localization and dynamics. These models support in vivo imaging studies of bone resorption.
Overexpression
Overexpression models are used to test whether increased levels of a gene enhance osteoclast-mediated bone resorption. Overexpression of microRNAs or lipid-related genes can reveal gain-of-function effects on resorption. These models complement knockout studies in defining gene function.
How EDITGENE Supports bone resorption Research
Researchers studying bone resorption-related genes often need to determine whether a candidate gene is causally involved in osteoclast-mediated degradation, whether a specific variant alters function, or whether overexpression is sufficient to drive resorptive activity. EDITGENE provides the CRISPR cell models and screening services needed to answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for bone resorption research.
Frequently Asked Questions About bone resorption
What is bone resorption (GO:0045453)?
Bone resorption (GO:0045453) is the biological process in which specialized cells known as osteoclasts degrade the organic and inorganic portions of bone, and endocytose and transport the degradation products.
What genes are involved in bone resorption?
Key genes include MMP9, MMP13, CTSK, NFATC1, TNFSF11, TNFRSF11A, TNFRSF11B, TCIRG1, CLCN7, and CA2, among others involved in osteoclast function and matrix degradation.
Which cells carry out bone resorption?
Osteoclasts are the specialized cells that carry out bone resorption, degrading both organic and inorganic bone matrix.
How is bone resorption regulated?
Bone resorption is regulated by microRNAs, lipids, and matrix metalloproteinases, as well as by signaling pathways controlling osteoclast differentiation and activity.
What diseases involve increased bone resorption?
Increased bone resorption is seen in osteoporosis, hemophilia-associated bone loss, chronic otitis media with bone destruction, and cancer-associated bone disease.
What is the role of MMPs in bone resorption?
Matrix metalloproteinases (MMPs) degrade the organic portion of bone matrix during resorption, remodeling, and repair.
How can bone resorption be measured in vivo?
Time-lapse imaging allows in vivo visualization and quantification of bone resorption and bone formation dynamics.
What is the difference between bone resorption and bone formation?
Bone resorption is the osteoclast-mediated degradation of bone, while bone formation is the deposition of new bone matrix; the two are coupled during remodeling.
Can CRISPR be used to study bone resorption genes?
Yes, CRISPR knockout, knock-in, point-mutation, and overexpression models are used to study genes involved in osteoclast-mediated bone resorption.
Why is bone resorption important for immunometabolism?
Bone resorption supports immunometabolism by releasing factors and handling degradation products that influence immune cell function.
Conclusion
Bone resorption (GO:0045453) is a fundamental biological process in which osteoclasts degrade the organic and inorganic portions of bone and transport the degradation products. Its regulation by microRNAs, lipids, and matrix metalloproteinases, and its dysregulation in diseases such as osteoporosis, hemophilia, and chronic otitis media, make it a central focus of musculoskeletal and translational research. Advances in in vivo imaging and CRISPR-based models continue to refine our understanding of this process and its therapeutic potential.
References
- 1. van Niekerk G et al.. 2018. Bone resorption: supporting immunometabolism.. Biol Lett 14(2) PMID: 29491030
- 2. Rodriguez-Merchan EC et al.. 2019. Increased bone resorption in hemophilia.. Blood Rev 33:6-10 PMID: 29857920
- 3. Ji L et al.. 2022. Regulation of osteoclast-mediated bone resorption by microRNA.. Cell Mol Life Sci 79(6):287 PMID: 35536437
- 4. Luo F et al.. 2025. Regulation of osteoclast-mediated bone resorption by lipids.. Bone 193:117423 PMID: 39933643
- 5. Paiva KBS et al.. 2017. Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair.. Prog Mol Biol Transl Sci 148:203-303 PMID: 28662823
- 6. Russell G et al.. 2001. Clinical disorders of bone resorption.. Novartis Found Symp 232:251-67; discussion 267-71 PMID: 11277085
- 7. Jung JY et al.. 2002. Bone resorption in chronic otitis media: the role of the osteoclast.. ORL J Otorhinolaryngol Relat Spec 64(2):95-107 PMID: 12021500
- 8. Christen P et al.. 2017. In vivo Visualisation and Quantification of Bone Resorption and Bone Formation from Time-Lapse Imaging.. Curr Osteoporos Rep 15(4):311-317 PMID: 28639146
